Operating CF
$10.80B
Capex
−$576.00M
Free Cash Flow
$10.23B
FCF Margin
+94.7%
Cash flow waterfall for Gilead Sciences (GILD) — TTM through Q1 2026
Free cash flow: $10.23B
Cash flow breakdown for Gilead Sciences (GILD) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $10.80B | $10.80B |
| Capital Expenditure | −$576.00M | $10.23B |
| Free Cash Flow | $10.23B | $10.23B |
| Acquisitions | −$906.00M | $9.32B |
| Other Investing | −$1.13B | $8.20B |
| Share Buybacks | −$1.61B | $6.59B |
| Dividends Paid | −$4.03B | $2.55B |
| Net Debt Change | −$2.79B | −$239.00M |
| Other Financing & FX | −$60.00M | −$299.00M |
| Net Cash Decrease | −$298.00M | −$298.00M |
- Operating Cash Flow$10.80B
- Capital Expenditure−$576.00M
- Free Cash Flow$10.23B
- Acquisitions−$906.00M
- Other Investing−$1.13B
- Share Buybacks−$1.61B
- Dividends Paid−$4.03B
- Net Debt Change−$2.79B
- Other Financing & FX−$60.00M
- Net Cash Decrease−$298.00M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement